Affordable Access

deepdyve-link
Publisher Website

Modified Oncolytic Herpesviruses for Gene Therapy of Cancer

Authors
  • Sivendran, Shanthi
  • Goldufsky, Joe
  • Kaufman, Howard
  • Saenger, Yvonne
Type
Book
Journal
Gene Therapy of Cancer
Publication Date
Jan 01, 2014
Pages
213–223
Identifiers
DOI: 10.1016/B978-0-12-394295-1.00015-9
ISBN: 978-0-12-394295-1
Source
Elsevier
Keywords
License
Unknown

Abstract

Herpes simplex viruses (HSV) possess unique functions as both oncolytic vectors and vaccines capable of initiating an innate host antitumor immune response and have been developed for the gene therapy of cancer. Modifications of viral genes encoding pathogenicity and immunogenicity proteins and insertion of eukaryotic immune enhancing genes have resulted in viral strains with selective tumor oncolytic and potent immunization potential with an acceptable safety profile and no neurotoxicity. Several modified HSV vectors are currently in clinical trials, with the most experience in the treatment of advanced melanoma. In this chapter, we discuss the basic biology of HSV, describe the origin of individual oncolytic HSV strains in clinical use, and present the results of clinical trials for melanoma and other human cancers.

Report this publication

Statistics

Seen <100 times